School of Life Science, Queen's Medical Centre, University of Nottingham, Nottingham, UK.
Institute of Mental Health, Mental Health and Clinical Neurosciences Academic Unit, University of Nottingham, Nottingham, UK.
Acta Neuropsychiatr. 2024 Feb;36(1):29-38. doi: 10.1017/neu.2023.27. Epub 2023 Jun 21.
Dementia with Lewy bodies (DLB) is the second most common dementia. Advancing our limited understanding of its molecular pathogenesis is essential for identifying novel biomarkers and therapeutic targets for DLB. DLB is an α-synucleinopathy, and small extracellular vesicles (SEV) from people with DLB can transmit α-synuclein oligomerisation between cells. Post-mortem DLB brains and serum SEV from those with DLB share common miRNA signatures, and their functional implications are uncertain. Hence, we aimed to investigate potential targets of DLB-associated SEV miRNA and to analyse their functional implications.
We identified potential targets of six previously reported differentially expressed miRNA genes in serum SEV of people with DLB (, , , , , and ) using and databases. We analysed functional implications of these targets using gene set enrichment analysis and analysed their protein interactions using pathway analysis.
These SEV miRNA may regulate 4278 genes that were significantly enriched among the genes involved in neuronal development, cell-to-cell communication, vesicle-mediated transport, apoptosis, regulation of cell cycle, post-translational protein modifications, and autophagy lysosomal pathway, after Benjamini-Hochberg false discovery rate correction at 5%. The miRNA target genes and their protein interactions were significantly associated with several neuropsychiatric disorders and with multiple signal transduction, transcriptional regulation, and cytokine signalling pathways.
Our findings provide evidence that potential targets of DLB-associated SEV miRNAs may contribute to Lewy pathology by transcriptional regulation. Experimental validation of these dysfunctional pathways is warranted and could lead to novel therapeutic avenues for DLB.
路易体痴呆(DLB)是第二常见的痴呆症。深入了解其分子发病机制对于确定 DLB 的新型生物标志物和治疗靶点至关重要。DLB 是一种α-突触核蛋白病,来自 DLB 患者的小细胞外囊泡(SEV)可以在细胞之间传递α-突触核蛋白寡聚化。DLB 患者死后的大脑和血清 SEV 具有共同的 miRNA 特征,但其功能意义尚不清楚。因此,我们旨在研究 DLB 相关 SEV miRNA 的潜在靶点,并分析其功能意义。
我们使用 和 数据库,鉴定了之前报道的 DLB 患者血清 SEV 中六种差异表达 miRNA 基因( 、 、 、 、 和 )的潜在靶点。我们使用 基因集富集分析分析了这些靶点的功能意义,并使用 途径分析分析了它们的蛋白质相互作用。
经过 Benjamini-Hochberg 假发现率校正后,这些 SEV miRNA 可能调节 4278 个基因,这些基因在神经元发育、细胞间通讯、囊泡介导的运输、细胞凋亡、细胞周期调节、翻译后蛋白修饰和自噬溶酶体途径中显著富集。在经过 Benjamini-Hochberg 假发现率校正后,这些 miRNA 靶基因及其蛋白质相互作用与多种神经精神疾病以及多个信号转导、转录调节和细胞因子信号通路显著相关。
我们的研究结果提供了 证据,表明 DLB 相关 SEV miRNA 的潜在靶点可能通过转录调节促进路易体病理学。有必要对这些功能失调的途径进行实验验证,这可能为 DLB 开辟新的治疗途径。